Successful preemptive Cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

Transplantation

Volumn 71, Issue 7, 2001, Pages 880-885

  Platzbecker, Uwe ^a   Bandt, Dirk ^a   Thiede, Christian ^a   Helwig, Anett ^a   Freiberg Richter, Jens ^a   Schuler, Ulrich ^a   Plettig, Runa ^a   Geissler, Gabriele ^a   Rethwilm, Axel ^a   Ehninger, Gerhard ^a   Bornhäuser, Martin ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PP65; BUSULFAN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; IDARUBICIN; IMMUNOGLOBULIN G; PROBENECID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DISEASE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEINURIA; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0035870754     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200104150-00010     Document Type: Article

References (27)

1. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
2. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte
3. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
4. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
5. CMV-antigenemia after allogeneic bone marrow transplantation: Correlation of CMV-antigen positive cell numbers with transplant-related mortality
6. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
7. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
8. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
9. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study
10. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients
11. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
12. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
13. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections
14. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia
15. Definitions of cytomegalovirus infection and disease: Multidisciplinary approach to understanding cytomegalovirus disease
16. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
17. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: A single-center experience
18. Cidofovir: A review of its use in cytomegalovirus retinitis in patients with AIDS
19. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine
20. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC)
21. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
22. Fludarabine: An update of its pharmacology and use in the treatment of haematological malignancies
23. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
24. Comparative analysis of chimerism in the early post transplantation period in cellular subsets of patients undergoing myeloablative and non-myeloablative allogeneic blood stem cell transplantation
25. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT
26. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
27. Risk factors for cytomegalovirus infection after human marrow transplantation